Psoriatic Arthritis: Perspectives

 
 
  • Non-Pharmacologic Therapies in PsO and PsA: 5 Things to Know While pharmacologic therapies remain central to managing PsO and PsA, non-pharmacologic interventions also play a crucial role in enhancing treatment outcomes and improving patients' quality of life.
  • Psoriasis: Presentation, Imitators, and Treatment Psoriasis is a disfiguring and often painful skin condition that affects an estimated 125 million people worldwide. Know the facts about this dermatologic issue.
  • Navigating PsA Treatment in Patients with Comorbidities PsA often coexists with a range of comorbidities, which can complicate treatment decisions. By tailoring treatment strategies, clinicians can improve outcomes for their patients.
  • Psoriatic Arthritis Highlights From ACR Convergence 2024   Highlights in psoriatic arthritis from ACR 2024 include results of methotrexate added to DMARD therapy, responses to bimekizumab, and improvements gained by upadacitinib after prior TNF inhibitor use.
  • MSWS 2024 Read clinically focused news coverage of key developments from MSWS 2024
  • The Role of Ultrasound in Psoriatic Arthritis Diagnosis Dr Philip J. Mease shares his insights on the use of ultrasound in psoriatic arthritis diagnosis, particularly in uncovering cases that are not obvious.
  • ACR 2024 Read clinically focused news coverage of key developments from ACR 2024
  • Psoriatic Disease and MASLD: What Is the Connection?   Dr Danielle Brandman explores the impact of metabolic dysfunction–associated steatotic liver disease (MASLD) in individuals with psoriatic disease.
  • FDA Drug Approvals Q3 2024 Stay current on FDA drug approvals July-September 2024
  • Are Genes Responsible for Causing Psoriasis? Research on the role that genes play in psoriasis has led to targeted therapies to reduce symptoms and slow disease progression.
  • Comorbidities Associated With Psoriasis: 5 Things to Know Psoriasis-associated comorbidities can have a significant impact on a patient's quality of life. Clinicians should be aware of these co-existing conditions for screening and appropriate co-management.
  • The NPF and the Future of Psoriatic Disease   National Psoriasis Foundation president and CEO Leah McCormick Howard discusses NPF resources to improve the lives of individuals living with psoriatic disease.
  • IBD Treatment Options After Failure of First-Line   When first-line anti–tumor necrosis factor treatment of inflammatory bowel disease fails, numerous options may be used in second-line. Dr Bincy Abraham discusses factors that inform the optimal choice.
  • The Role of Cytokines in Psoriasis: 5 Things to Know Research on the role that cytokines play in psoriasis has led to targeted therapies to reduce symptoms and slow disease progression.
  • Treating Psoriatic Arthritis in Primary Care A rheumatologist reviews the main updates to the European Alliance of Associations for Rheumatology's 2019 recommendations.
  • GRAPPA 2024 Read clinically focused news coverage of key developments from GRAPPA 2024
  • FDA Drug Approvals Q2 2024 Stay current on FDA drug approvals April-June 2024
  • Psoriasis and Cardiovascular Effects: A Vital Connection   Dr Joel Gelfand, Dr Michael Garshick, and Leah McCormick Howard discuss the connection between psoriasis and cardiovascular disease and how to work toward optimal outcomes for patients.
  • Advancements in Biologic Therapies for Psoriatic Arthritis   Biologic therapies are transforming management of psoriatic arthritis. Drs Alexis Ogdie and Jose Scher discuss how newer biologic therapies are improving response and outcomes.
  • BSR 2024 Read clinically focused news coverage of key developments from BSR 2024